Ratings
0
Nobody has rated this yet. Be the first!
Works
13
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
Update on the treatment of disseminated fusariosis: Focus on voriconazole.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o
